Professionals highlight considerations for the addition of cost-effective, statistically significant therapies to payer formularies.
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Parekh discusses the high prevalence of dry eye disease (DED), accelerated by digital device use and mask wearing during COVID-19. Resulting issues like eye fatigue and secondary keratitis lead to lost workplace productivity, both outside and remote settings. The worldwide DED market represents billions in costs. Various pipeline innovations signal the broad need for a multidimensional treatment landscape to address heterogeneous DED subtypes. Lack of early DED control risks long-term visual impairment. Comprehensive DED insurance coverage is thus as warranted as for other chronic diseases to optimize outcomes and costs.
Kabiri notes secondary issues like neurotrophic keratitis and the need for treatments like serum tears after DED progression require high costs. Earlier control of the evaporative DED component could prevent downstream issues in a more cost-effective manner. Haumschild concurs, highlighting the high costs of uncontrolled DED, including greater health care utilization, lost workplace productivity, and staff shortages. Optimal DED management early on can mitigate adverse outcomes and costs.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Care Quality Metrics in Medicare During COVID-19 Pandemic
August 12th 2025Medicare Advantage outperformed traditional Medicare on clinical quality measures before and during the COVID-19 pandemic; mid-pandemic, however, traditional Medicare narrowed the gap on some in-person screenings.
Read More
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More